It appears that the E. coli isolates showed significantly higher rates of resistance (p < 0.05) in cancer patients compared to noncancer patients to AMX (87.83% vs. 66.67%), AMC (59.13% vs. 27.59%), CXM (80.87% vs. 39.08%), PRL (95.65% vs. 51.72%), CTR (66,09% vs. 34.48%), CAZ (68.70% vs. 27.59%), CIP (46.09% vs. 31.03%), OFX (47.83% vs. 32.18%), NAL (60, 87% vs. 49.43%), COL (60.87% vs. 24.14%), TET (89.57% vs. 63.22%), and ERY (75.65% vs. 29.89%). This evidence concerns the gene NPL and cancer.